Compare EVO & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | LGIH |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | EVO | LGIH |
|---|---|---|
| Price | $2.73 | $41.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $75.90 |
| AVG Volume (30 Days) | 95.9K | ★ 422.6K |
| Earning Date | 04-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $1,705,504,000.00 |
| Revenue This Year | $1.37 | $2.32 |
| Revenue Next Year | $10.05 | $17.94 |
| P/E Ratio | ★ N/A | $450.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $33.55 |
| 52 Week High | $4.80 | $69.42 |
| Indicator | EVO | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 41.02 |
| Support Level | $2.32 | $35.87 |
| Resistance Level | $3.78 | $41.50 |
| Average True Range (ATR) | 0.09 | 2.15 |
| MACD | -0.06 | -0.77 |
| Stochastic Oscillator | 19.16 | 10.21 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.